Cardiff Oncology, Inc. (FRA:XE7C)

Germany · Delayed Price · Currency is EUR

1.750

+0.076 (4.54%)

At close: Dec 4, 2025

-26.78% (1Y)

Market Cap	122.18M
Revenue (ttm)	427.00K
Net Income (ttm)	-43.00M
Shares Out	n/a
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.750
Previous Close	1.674
Day's Range	1.750 - 1.750
52-Week Range	1.602 - 5.030
Beta	n/a
RSI	48.64
Earnings Date	Feb 27, 2026

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 33

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol XE7C

Full Company Profile

Financial Performance

In 2024, Cardiff Oncology's revenue was $683,000, an increase of 39.96% compared to the previous year's $488,000. Losses were -$45.46 million, 9.62% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.